GILD News 107.41 08/28/2014 05:10:29 Gilead Sciences (GILD)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gilead Sciences (GILD) 107.41 $GILD

Global Cytomegalovirus Retinitis Market Report 2014 - Forecasts to 2018
M2 - 1 hr 1 min ago
Research and Markets (http://www.researchandmarkets.com/research/5rhbrc/global) has announced the addition of the "Global Cytomegalovirus Retinitis Market 2014-2018" report to their offering. The Global Cytomegalovirus Retinitis market to grow at a CAGR of 4.50 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Cytomegalovirus Retinitis market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various branded and generic drugs used for the treatment of cytomegalovirus retinitis. Capsules, implants, solutions, and tablets are the four dosage forms of the drugs used for the treatment of cytomegalovirus retinitis. An increase in combination therapies for the treatment of cytomegalovirus retinitis is a major trend emerging in the market. These therapies lower drug resistance in patients and ensure more effective action of the drug. According to the report, the Global Cytomegalovirus Retinitis market is experiencing a large number of unmet needs. Currently, Roche's Valcyte is the only branded drug available for the treatment of this indication. The market has also observed the use of off-label drugs for the treatment of cytomegalovirus retinitis. Further, the report states that one of the major challenges in the market is a lack of approved treatment guidelines by the WHO, which is responsible for the negligence of the treatment of cytomegalovirus retinitis worldwide. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Key Vendors - F. Hoffmann-La Roche - Gilead Sciences - Hospira - Shire Other Prominent Vendors - Auritec Pharmaceuticals - Chimerix Pharmaceuticals - Isis Pharmaceuticals - pSivida - Sanofi For more information visit http://www.researchandmarkets.com/research/5rhbrc/global

Most active Nasdaq-traded stocks
AP - Wed Aug 27, 5:03PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:

Final Glance: Biotechnology companies
AP - Wed Aug 27, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:

After Yesterday's Rally of 1.07% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Aug 27, 3:38PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.76 to a high of $108.77. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $108.72 on volume of 16.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Look for Shares of Gilead Sciences to Potentially Pullback after Yesterday's 1.07% Rise
Comtex SmarTrend(R) - Wed Aug 27, 3:37PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.76 to a high of $108.77. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $108.72 on volume of 16.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Gilead Sciences (GILD) Approaches New Upside Target of $110.54
Comtex SmarTrend(R) - Wed Aug 27, 11:42AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $106.59 and have already reached the first level of resistance at $108.40. Investors may be interested in a cross of the next upside pivot targets of $110.54 and $114.49.

Bristol-Myers Hepatitis C Therapy Approved in EU
at Investor's Business Daily - Wed Aug 27, 11:03AM CDT
Bristol-Myers Squibb (BMY) won approval for its oral hepatitis C virus (HCV) drug Daklinza in the European Union Wednesday, as the company continued to carve out a niche in the increasingly competitive HCV space. The EU approved Daklinza with...

Goldman Sachs' 50 Stocks That Matter Most to Hedge Funds
at The Street - Wed Aug 27, 9:58AM CDT
This list of 50 stocks from Goldman Sachs Spreadsheet are those that appear most frequently among the top holdings of hedge funds. The portfolio beat the S&P 500 YTD gain.

Is It Time to Buy AbbVie Stock?
Keith Speights, The Motley Fool - Motley Fool - Wed Aug 27, 9:45AM CDT
One month after two big announcements, the dust has settled somewhat for AbbVie . Those major announcements, of course, were a blow-out second quarter and the acquisition of Shire plc . In the first few days after the news hit the street,...

Early Glance: Biotechnology companies
AP - Wed Aug 27, 9:18AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:

Amicus Therapeutics Hits 52-Week High on Migalastat Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:49AM CDT
Shares of Amicus Therapeutics (FOLD) hit a 52-week high of $6.28 during the trading session on Aug 26.

Kite Pharma (KITE) Shows Strength: Stock Rises 17.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:39AM CDT
Kite Pharma, Inc. (KITE) was a big mover last session, as its shares rose almost 18% on the day.

China Biologic Products, Inc. (CBPO) Rises: Stock Jumps 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:32AM CDT
China Biologic Products, Inc. (CBPO) was a big mover last session, as the company saw its shares rise more than 7% on the day.

3 Reasons Pfizer Inc.'s Stock Could Fall
Sean Williams, The Motley Fool - Motley Fool - Wed Aug 27, 8:22AM CDT
Pfizer may be the largest pharmaceutical company in the world, but size isn't everything when it comes to developing and selling drugs. Over the past 16 years Pfizer's stock hasn't budged on a nominal basis. That doesn't mean Pfizer's management...

Roche, InterMune a Strategic Play in Midst of Inversions
at The Street - Wed Aug 27, 8:19AM CDT
As more companies seek tax savings through inversions, strategic reasons still remain for drug company deals.

Isis Pharmaceuticals, Inc. (ISIS) Surges: Stock Moves 10.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:11AM CDT
Isis Pharmaceuticals, Inc. (ISIS) was a big mover last session, as the company saw its shares rise by nearly 11% on the day.

Upcoming Conference Schedule, Scholarship, Approved Supplemental New Drug Application, and Technical Updates - Research Reports on Gilead, AbbVie, Pfizer, Express Scripts and Bard
PR Newswire - Wed Aug 27, 8:10AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), Express Scripts Holding Company (NASDAQ: ESRX) and C.R. Bard, Inc. (NYSE: BCR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5998-100free.

Celldex Therapeutics (CLDX) Worth Watching: Stock Rises 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:51AM CDT
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as its shares rose a little over 9% on the day.

Achillion Pharmaceuticals (ACHN) Jumps: Stock Adds 9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:37AM CDT
Achillion Pharmaceuticals, Inc. (ACHN) was a big mover last session, as the company saw its shares rise 9% on the day.

Gilead, Jazz Among 4 Top Big Cap Medicals To Watch
at Investor's Business Daily - Wed Aug 27, 7:02AM CDT
Today's Screen of the Day features four institutional-quality drug and medical Big Caps stocks with solid fundamentals. Jazz Pharmaceuticals (JAZZ), which has a market cap of $9.85 billion, earned an IBD Composite Rating of 99, which means that it...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kansai Powers Up US Grid with Bold Investment Move

Updated Category News Views 128

Betting Big on Battery Storage Let's unpack this big move by Kansai Electric. Anytime a major player like Kansai steps out of its home turf, folks better pay attention. Looks like Kansai's gotten cozy with Elevate and ArcLight, nabbing a minority stake in Prospect Power. This ain't your average widget factory—it's a beefy 150MW/600MWh battery energy storage facility in...

Continue Reading
RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 154

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
Kinross Gold Faces Class Action Over Misleading Forecasts

Updated Category News Views 68

A Golden Opportunity Gone Wrong Well, it looks like Kinross Gold Corporation (NYSE: KGC) has stuck its foot in it again. This time, they're in hot water over claims that don't exactly hold up under scrutiny. If you're holding KGC, you've probably heard about the fresh class action lawsuit alleging they misled investors about their production targets. Naturally, the...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 120

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 65

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 63

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 122

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 111

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 106

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading

Top 5 Most Recently Viewed Articles

Radiant Striping's Community Commitment through Service Initiatives

Updated Category News Views 144

Radiant Striping's Charitable Impact on the Community Radiant Striping, a veteran-owned company, is making waves in their community through generous donations of parking lot striping and other services to local organizations. It's not just about the perfect paint job; it’s about building safer, more welcoming spaces for families and visitors alike. A Mission Rooted in...

Continue Reading
Supernus Pharmaceuticals Announces Participation in Key Healthcare Event

Updated Category News Views 86

Supernus Pharmaceuticals' Participation in the Healthcare Conference Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a dedicated biopharmaceutical company, is excited to announce its upcoming participation in a significant healthcare conference. The conference will take place soon, and prominent figures from the company, including Jack Khattar, President and CEO, are set...

Continue Reading
CTC Celebrated as Top Veteran-Friendly Employer in 2024

Updated Category News Views 70

Concurrent Technologies Corporation Recognized in 2024 Concurrent Technologies Corporation (CTC) is thrilled to announce its inclusion in the U.S. Veterans Magazine’s Top Veteran-Friendly Employers list for 2024. This achievement marks the fourth consecutive year that CTC has received this important recognition. How U.S. Veterans Magazine Evaluates Employers Each year,...

Continue Reading
Chimerix Announces Inducement Grant of Stock Options

Updated Category News Views 188

Chimerix Announces Inducement Grant of Stock Options Chimerix (NASDAQ:CMRX), a prominent biopharmaceutical company, has announced a notable inducement award for a newly hired employee. This grant includes non-statutory stock options totaling 150,000 shares of the company's common stock, underscoring Chimerix's dedication to attracting top talent in the competitive biotech...

Continue Reading
EarFun Showcases Cutting-Edge Wireless Audio Innovations

Updated Category News Views 620

Discover the Latest Innovations from EarFun at CES 2025 EarFun, a prominent name in wireless audio technology, is set to unveil a range of cutting-edge products that will redefine the audio experience. Their participation in CES 2025 promises to highlight significant advancements that cater to diverse listening needs. Innovative AI-Powered Features The spotlight will be...

Continue Reading